Publications by authors named "Sarah N Powers"
Vascular endothelial growth factor receptor inhibitors (VEGFRis) improve cancer survival but are associated with treatment-limiting hypertension, often attributed to endothelial cell (EC) dysfunction. Using phosphoproteomic profiling of VEGFRi-treated ECs, drugs were screened for mitigators of VEGFRi-induced EC dysfunction and validated in primary aortic ECs, mice, and canine cancer patients. VEGFRi treatment significantly raised systolic blood pressure (SBP) and increased markers of endothelial and renal dysfunction in mice and canine cancer patients.
View Article and Find Full Text PDFArticle Synopsis
- Cardiolipin is crucial for mitochondrial function and is impacted by VA-ECMO, which is used in treating acute myocardial infarction, but its effects on heart damage are not well understood.
- The study found that both human patients requiring VA-ECMO and healthy swine subjected to this treatment showed significantly lower levels of cardiolipin and the enzyme tafazzin, indicating potential detrimental effects on the heart.
- Importantly, VA-ECMO increased heart damage during ischemia/reperfusion, evidenced by a larger infarct size in swine, suggesting that depleting cardiolipin during treatment may worsen myocardial injury.